A citation-based method for searching scientific literature

Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
Times Cited: 5







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
263
60

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
60

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
60

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
40

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
40

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
399
40


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
40

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
40

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
150
40

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
40

Cellular and Molecular Mechanisms of Metformin Action.
Traci E LaMoia, Gerald I Shulman. Endocr Rev 2021
31
40

Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?
Theocharis Koufakis, Nikolaos Papanas, George Dimitriadis, Pantelis Zebekakis, Kalliopi Kotsa. J Diabetes 2020
8
40

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
233
40

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
40


Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel.
Dahlia Weitzman, Gabriel Chodick, Varda Shalev, Chagai Grossman, Ehud Grossman. Hypertension 2014
57
20

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
247
20

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
187
20

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
David C Wheeler, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto,[...]. Lancet Diabetes Endocrinol 2021
53
20

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, Fahri Bayram, Patrice Darmon, Timothy M E Davis, Guillermo Dieuzeide, Kirsten T Eriksen, Tianpei Hong, Margit S Kaltoft,[...]. Cardiovasc Diabetol 2021
2
50

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
92
20

SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Jin-Song Gu, Xian Zhou, Ying-Xi Tang, Xu-Bin Wei, Shu-Yan Liu. Pharmacol Res 2020
4
25

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
188
20


Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
David D Berg, Stephen D Wiviott, Benjamin M Scirica, Yared Gurmu, Ofri Mosenzon, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Circulation 2019
45
20


Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
15
20

The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization.
Varda Shalev, Gabriel Chodick, Iris Goren, Haim Silber, Ehud Kokia, Anthony D Heymann. Int J Cardiol 2011
71
20

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.
Ian H de Boer, M Luiza Caramori, Juliana C N Chan, Hiddo J L Heerspink, Clint Hurst, Kamlesh Khunti, Adrian Liew, Erin D Michos, Sankar D Navaneethan, Wasiu A Olowu,[...]. Kidney Int 2020
43
20

Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes.
Anke Schwandt, Michael Denkinger, Peter Fasching, Martin Pfeifer, Christian Wagner, Jörg Weiland, Andrej Zeyfang, Reinhard W Holl. J Diabetes Complications 2017
43
20

High-normal albuminuria and risk of heart failure in the community.
Saul Blecker, Kunihiro Matsushita, Anna Köttgen, Laura R Loehr, Alain G Bertoni, L Ebony Boulware, Josef Coresh. Am J Kidney Dis 2011
68
20

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito. Cardiovasc Diabetol 2021
11
20

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
199
20


Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
Yan Xie, Benjamin Bowe, Andrew K Gibson, Janet B McGill, Yan Yan, Geetha Maddukuri, Ziyad Al-Aly. Diabetes Care 2020
15
20

DECLARE-TIMI 58: Participants' baseline characteristics.
Itamar Raz, Ofri Mosenzon, Marc P Bonaca, Avivit Cahn, Eri T Kato, Michael G Silverman, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Diabetes Obes Metab 2018
73
20


The epidemiology of diabetes in a large Israeli HMO.
Gabriel Chodick, Anthony D Heymann, Varda Shalev, Ehud Kookia. Eur J Epidemiol 2003
100
20

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri,[...]. Lancet Diabetes Endocrinol 2020
28
20

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Benjamin M Scirica, Ofri Mosenzon, Deepak L Bhatt, Jacob A Udell, Ph Gabriel Steg, Darren K McGuire, KyungAh Im, Estella Kanevsky, Christina Stahre, Mikaela Sjöstrand,[...]. JAMA Cardiol 2018
45
20


Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
Brad C Astor, Kunihiro Matsushita, Ron T Gansevoort, Marije van der Velde, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Brad C Astor, Kunihiro Matsushita,[...]. Kidney Int 2011
444
20

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
20

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Kåre I Birkeland, Johan Bodegard, Anna Norhammar, Josephina G Kuiper, Elena Georgiado, Wendy L Beekman-Hendriks, Marcus Thuresson, Marc Pignot, Ron M C Herings, Adriaan Kooy. Diabetes Obes Metab 2019
40
20

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, Jamie P Dwyer, Avivit Cahn, Erica L Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A Murphy,[...]. Diabetes Care 2021
3
33

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray,[...]. Lancet 2019
174
20

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
20
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.